Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DEBABRATA BANDYOPADHYAY

Allopathic & Osteopathic Physicians Internal Medicine Critical Care Medicine

NPI
1942431135
CMS profile
2762790
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$72,079.84

74 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
United Therapeutics Corporation $52,357.35 55
Boehringer Ingelheim Pharmaceuticals, Inc. $19,229.20 13
Genentech, Inc. $469.48 4
Astellas Pharma US Inc $23.81 2

Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DEBABRATA BANDYOPADHYAY

NPI 1942431135 · CMS profile ID 2762790

Allopathic & Osteopathic Physicians / Internal Medicine / Critical Care Medicine

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1942431135?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DEBABRATA BANDYOPADHYAY, NPI 1942431135, CMS profile ID 2762790. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942431135?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DEBABRATA BANDYOPADHYAY, NPI 1942431135, CMS profile ID 2762790. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942431135?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DEBABRATA BANDYOPADHYAY, NPI 1942431135, CMS profile ID 2762790, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1942431135?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

74 matching records · $72,079.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 74 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–74 of 74.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
United Therapeutics Corporation $1,270.0006/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839137903 CMS
United Therapeutics Corporation $4,900.0006/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839137897 CMS
United Therapeutics Corporation $155.5206/24/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839137899 CMS
United Therapeutics Corporation $24.8906/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839137901 CMS
United Therapeutics Corporation $353.3406/23/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839137887 CMS
United Therapeutics Corporation $22.1506/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839137889 CMS
United Therapeutics Corporation $480.5106/23/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839137891 CMS
United Therapeutics Corporation $6,000.0006/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839137893 CMS
United Therapeutics Corporation $125.0406/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839137895 CMS
United Therapeutics Corporation $12.0006/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839129829 CMS
United Therapeutics Corporation $392.1506/14/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839137879 CMS
United Therapeutics Corporation $148.4506/14/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839137881 CMS
United Therapeutics Corporation $125.0306/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839137885 CMS
United Therapeutics Corporation $3,400.0006/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839146583 CMS
United Therapeutics Corporation $31.7206/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839129831 CMS
United Therapeutics Corporation $27.3505/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839129827 CMS
Genentech, Inc. $49.9504/23/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835904311 CMS
United Therapeutics Corporation $820.0004/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839137877 CMS
United Therapeutics Corporation $1,640.0004/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839137875 CMS
Genentech, Inc. $135.5304/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835904303 CMS
United Therapeutics Corporation $2,000.0003/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839126867 CMS
United Therapeutics Corporation $18.3403/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839126873 CMS
United Therapeutics Corporation $138.8103/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839126435 CMS
United Therapeutics Corporation $106.9901/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839126433 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $771.83 11
PY2020 $21,632.46 25
PY2021 $72,079.84 74
PY2022 $78,525.70 117
PY2023 $76,617.15 86
PY2024 $50,850.49 65
PY2025 $97,316.15 107

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $543,089.77 112
PY2024 Principal investigator $501,136.75 108
PY2023 Principal investigator $389,007.36 54
PY2022 Principal investigator $83,787.65 12
PY2021 Principal investigator $10,500.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

112 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 United Therapeutics Corporation $665.00 12/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389979
Principal investigator 1 United Therapeutics Corporation $2,519.50 12/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389989
Principal investigator 1 United Therapeutics Corporation $665.00 12/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390023
Principal investigator 1 United Therapeutics Corporation $6,215.40 12/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390043
Principal investigator 1 United Therapeutics Corporation $33.75 12/10/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390009
Principal investigator 1 United Therapeutics Corporation $600.75 12/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389885
Principal investigator 1 United Therapeutics Corporation $2,802.00 12/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389893
Principal investigator 1 United Therapeutics Corporation $10,786.50 12/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389903
Principal investigator 1 United Therapeutics Corporation $90.00 11/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389967
Principal investigator 1 United Therapeutics Corporation $595.00 11/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389977
Principal investigator 1 United Therapeutics Corporation $4,412.90 11/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389999
Principal investigator 1 United Therapeutics Corporation $213.75 11/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390013
Principal investigator 1 United Therapeutics Corporation $595.00 11/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390019
Principal investigator 1 United Therapeutics Corporation $659.30 11/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390021
Principal investigator 1 United Therapeutics Corporation $1,960.00 11/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389987
Principal investigator 1 United Therapeutics Corporation $1,960.00 11/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390035
Principal investigator 1 United Therapeutics Corporation $13,084.20 11/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390053
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,868.79 11/05/2025 Non-covered Recipient Entity
Tampa General Hospital Specialty Pharmacy
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220792633
Principal investigator 1 United Therapeutics Corporation $90.00 10/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389965
Principal investigator 1 United Therapeutics Corporation $1,275.00 10/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390031
Principal investigator 1 United Therapeutics Corporation $12,465.90 10/10/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389907
Principal investigator 1 United Therapeutics Corporation $1,750.00 09/25/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389889
Principal investigator 1 United Therapeutics Corporation $8,406.00 09/25/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389901
Principal investigator 1 United Therapeutics Corporation $32,359.50 09/25/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389913
Principal investigator 1 United Therapeutics Corporation $2,790.45 09/16/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390095
Principal investigator 1 United Therapeutics Corporation $270.00 09/10/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389971
Principal investigator 1 United Therapeutics Corporation $4,112.90 09/10/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389997
Principal investigator 1 United Therapeutics Corporation $8,485.25 09/10/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390047
Principal investigator 1 United Therapeutics Corporation $595.00 09/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390083
Principal investigator 1 United Therapeutics Corporation $5,432.40 08/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390001
Principal investigator 1 United Therapeutics Corporation $4,400.15 08/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390039
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $553.80 08/26/2025 Non-covered Recipient Entity
Tampa General Hospital Specialty Pharmacy
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220792629
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $170.30 08/26/2025 Non-covered Recipient Entity
Tampa General Hospital Specialty Pharmacy
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220792631
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,414.27 08/06/2025 Non-covered Recipient Entity
Tampa General Hospital Specialty Pharmacy
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220792627
Principal investigator 1 United Therapeutics Corporation $2,802.00 07/31/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389895
Principal investigator 1 United Therapeutics Corporation $10,786.50 07/31/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389905
Principal investigator 1 United Therapeutics Corporation $4,112.90 07/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389995
Principal investigator 1 United Therapeutics Corporation $1,305.00 07/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390033
Principal investigator 1 United Therapeutics Corporation $10,858.05 07/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390051
Principal investigator 1 United Therapeutics Corporation $21,263.85 07/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390105
Principal investigator 1 United Therapeutics Corporation $2,000.00 07/10/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389891
Principal investigator 1 United Therapeutics Corporation $1,260.00 07/08/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389985
Principal investigator 1 United Therapeutics Corporation $1,260.00 07/08/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390029
Principal investigator 1 United Therapeutics Corporation $270.00 07/08/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390071
Principal investigator 1 United Therapeutics Corporation $16,621.20 07/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389909
Principal investigator 1 United Therapeutics Corporation $2,794.50 06/25/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389991
Principal investigator 1 United Therapeutics Corporation $33.75 06/25/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390007
Principal investigator 1 United Therapeutics Corporation $8,613.00 06/25/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390049
Principal investigator 1 United Therapeutics Corporation $135.00 06/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390063
Principal investigator 1 United Therapeutics Corporation $270.00 06/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390069
Principal investigator 1 United Therapeutics Corporation $375.00 06/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390075
Principal investigator 1 United Therapeutics Corporation $3,300.00 06/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390099
Principal investigator 1 United Therapeutics Corporation $1,050.00 06/11/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389983
Principal investigator 1 United Therapeutics Corporation $1,050.00 06/11/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390027
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,850.77 06/04/2025 Non-covered Recipient Entity
Tampa General Hospital Specialty Pharmacy
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220792625
Principal investigator 1 United Therapeutics Corporation $135.00 05/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390061
Principal investigator 1 United Therapeutics Corporation $500.00 05/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390081
Principal investigator 1 United Therapeutics Corporation $9,938.70 05/21/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390005
Principal investigator 1 United Therapeutics Corporation $7,620.75 05/21/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390045
Principal investigator 1 United Therapeutics Corporation $1,330.00 05/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390091
Principal investigator 1 United Therapeutics Corporation $180.00 05/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389969
Principal investigator 1 United Therapeutics Corporation $595.00 05/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389975
Principal investigator 1 United Therapeutics Corporation $3,154.50 05/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389993
Principal investigator 1 United Therapeutics Corporation $6,893.50 05/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390003
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $365.82 05/01/2025 Non-covered Recipient Entity
Tampa General Hospital Specialty Pharmacy
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220792621
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $145.11 05/01/2025 Non-covered Recipient Entity
Tampa General Hospital Specialty Pharmacy
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220792623
Principal investigator 1 United Therapeutics Corporation $90.00 04/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390055
Principal investigator 1 United Therapeutics Corporation $90.00 04/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390011
Principal investigator 1 United Therapeutics Corporation $595.00 04/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390017
Principal investigator 1 United Therapeutics Corporation $2,118.65 04/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390037
Principal investigator 1 United Therapeutics Corporation $135.00 04/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390059
Principal investigator 1 United Therapeutics Corporation $840.00 04/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390085
Principal investigator 1 United Therapeutics Corporation $350.00 04/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389973
Principal investigator 1 United Therapeutics Corporation $350.00 04/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390015
Principal investigator 1 United Therapeutics Corporation $4,596.75 04/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390041
Principal investigator 1 United Therapeutics Corporation $16,621.20 04/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389911
Principal investigator 1 United Therapeutics Corporation $90.00 03/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389953
Principal investigator 1 United Therapeutics Corporation $270.00 03/06/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390067
Principal investigator 1 United Therapeutics Corporation $1,000.00 03/06/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390089
Principal investigator 1 United Therapeutics Corporation $3,000.00 03/06/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390097
Principal investigator 1 United Therapeutics Corporation $19,149.75 02/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389951
Principal investigator 1 United Therapeutics Corporation $6,924.15 02/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389959
Principal investigator 1 United Therapeutics Corporation $700.00 02/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389981
Principal investigator 1 United Therapeutics Corporation $700.00 02/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242390025
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $29,279.53 02/12/2025 Non-covered Recipient Entity
The University Of South Florida Board Of Trustees
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis No dispute reported 06/30/2026 1235992977
Principal investigator 1 United Therapeutics Corporation $210.88 02/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389939
Principal investigator 1 United Therapeutics Corporation $365.54 02/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389941
Principal investigator 1 United Therapeutics Corporation $674.26 02/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389943
Principal investigator 1 United Therapeutics Corporation $1,155.00 02/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389945
Principal investigator 1 United Therapeutics Corporation $2,787.75 02/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389947
Principal investigator 1 United Therapeutics Corporation $8,880.30 02/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389949
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,714.76 02/03/2025 Non-covered Recipient Entity
Tampa General Hospital Specialty Pharmacy
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220792611
Principal investigator 1 United Therapeutics Corporation $500.00 01/29/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389955
Principal investigator 1 United Therapeutics Corporation $1,155.00 01/29/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242389957
Principal investigator 1 United Therapeutics Corporation $12,231.00 01/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390103
Principal investigator 2 E.R. Squibb & Sons, L.L.C. $1,758.70 01/21/2025 Non-covered Recipient Entity
Tampa General Hospital
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis No dispute reported 06/30/2026 1235993377
Principal investigator 1 United Therapeutics Corporation $276.35 01/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390073
Principal investigator 2 E.R. Squibb & Sons, L.L.C. $129,375.25 01/13/2025 Non-covered Recipient Entity
The University Of South Florida Board Of Trustees
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1235992975
Principal investigator 1 United Therapeutics Corporation $4,155.30 01/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389897
Principal investigator 1 United Therapeutics Corporation $945.00 01/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390087
Principal investigator 1 United Therapeutics Corporation $1,610.00 01/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390093
Principal investigator 1 United Therapeutics Corporation $1,401.00 01/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389887
Principal investigator 1 United Therapeutics Corporation $5,393.25 01/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389899
Principal investigator 1 United Therapeutics Corporation $135.00 01/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390057
Principal investigator 1 United Therapeutics Corporation $180.00 01/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390065
Principal investigator 1 United Therapeutics Corporation $400.00 01/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390077
Principal investigator 1 United Therapeutics Corporation $500.00 01/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390079
Principal investigator 1 United Therapeutics Corporation $6,000.00 01/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242390101
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $596.40 01/01/2025 Non-covered Recipient Entity
Tampa General Hospital Specialty Pharmacy
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220792613
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $313.56 01/01/2025 Non-covered Recipient Entity
Tampa General Hospital Specialty Pharmacy
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220792615
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $183.40 01/01/2025 Non-covered Recipient Entity
Tampa General Hospital Specialty Pharmacy
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220792617
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $124.38 01/01/2025 Non-covered Recipient Entity
Tampa General Hospital Specialty Pharmacy
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220792619